Cingulate Provides 2022 Clinical Plan for CTx-1301, an Investigational Medication for Attention Deficit/Hyperactivity Disorder (ADHD)
Specifically, the pivotal, fixed-dose study is slated to begin in the second quarter of 2022.
- Specifically, the pivotal, fixed-dose study is slated to begin in the second quarter of 2022.
- These studies allow Cingulate to compile a robust data set for our FDA filing, providing clinicians and payers clear evidence of the potential benefits of CTx-1301.
- Attention Deficit/Hyperactivity Disorder (ADHD) is a chronic neurobiological and developmental disorder that affects millions of children and often continues into adulthood.
- Among this group, approximately 80 percent receive treatment, with 65 percent demonstrating clinical ADHD symptoms that persist into adulthood.